Financial Data and Key Metrics Changes - Fourth quarter revenue totaled $556.1 million, representing a year-over-year growth of 45.4%, at the top end of the guidance range [25] - Adjusted EBITDA for the fourth quarter was $48.1 million, reflecting a growth of 48.9% [25] - For the full year 2023, revenue reached $1.96 billion, also a 45% year-over-year growth, with adjusted EBITDA totaling $194.7 million [52] Business Line Data and Key Metrics Changes - Evolent's core specialty care offerings accounted for 88% of total revenue in the fourth quarter, with specialty care revenue growing approximately 74% year-over-year [25] - The NIA acquisition contributed approximately 19% to reported growth, while 55% of the growth came from organic sources [25] Market Data and Key Metrics Changes - The company experienced a gross Medicaid membership decline of 8.5% on a same-store basis, with expectations of a total decline in the mid-teens by mid-2024 [91] - In Medicare Advantage, which represents about 42% of revenue, there has been elevated utilization, particularly for inpatient and supplemental benefit cost drivers [68] Company Strategy and Development Direction - The company is focused on strong organic growth, profitability, and disciplined capital allocation as guiding principles [27] - Evolent is expanding its Performance Suite into advanced imaging and has signed new revenue agreements to enhance its service offerings [55][56] - The company aims to achieve a $300 million adjusted EBITDA run rate exit target for 2024, with a strong pipeline of new revenue agreements [24][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the $300 million adjusted EBITDA target, citing consistent performance across several years [7] - The company noted that headwinds from Medicaid redeterminations are mostly behind them, with expectations for continued organic growth [71] - Management highlighted the importance of engaging partners to manage specialty care costs effectively, which is increasingly sought after by health plans [57] Other Important Information - The company ended 2023 with a cash balance of $193 million, exceeding its goal of increasing cash by more than $120 million [41] - Evolent's average product members grew to almost 80 million for the quarter, despite challenges in the Medicaid segment [26] Q&A Session Summary Question: How does the new Performance Suite offering impact market sizing? - Management indicated that the new offering does increase the total addressable market, although it remains a small portion of the overall market [123] Question: What is the expected impact of the Medicaid redeterminations? - Management confirmed that the impact aligns with expectations, with a projected decline in membership and a modest increase in utilization metrics [91] Question: What are the paths to achieve the $4 million EBITDA target? - Management noted multiple paths to achieve the target, primarily through Technology and Services, and emphasized a strong pipeline of opportunities [76] Question: How does the company view the expansion of Performance Suite outside of Florida and Arizona? - Management stated that expansion opportunities exist but emphasized the importance of delivering outstanding performance first [115][132]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-37415 _________________________ Evolent Health, Inc. (Exact name of registrant as specified in its charter) _________________________ (State or other jurisdiction of incorporation or organization) Delaware 32-0454912 WASHINGTON, D.C. 20549 _________________________ FORM 10-K _________________________ (Mark One) S ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December ...

WASHINGTON, Feb. 14, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today appointed Russell Glass to its Board of Directors. Glass has almost 25 years of experience as a successful technology and health care executive who currently serves as Chief Executive Officer of Headspace, a pioneering company focused on digitally enabled mental hea ...

Evolent Health, Inc. (NYSE:EVH) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Seth Frank - Vice President, Investor Relations Seth Blackley - Chief Executive Officer, Co-Founder & Board Member John Johnson - Chief Financial Officer Conference Call Participants Ryan Daniels - William Blair Kevin Caliendo - UBS Unknown speaker - Guggenheim Partners Charles Rhyee - TD Cowen Jeff Garro - Stephens Inc Richard Close - Canaccord Genuity David Larsen - BTIG Sean Dodge - RBC Capit ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________ FORM 10-Q _________________________ (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 _________________________ Evolent Health, Inc. (Exact name of reg ...

| --- | --- | |-----------------------------|-------| | | | | | | | | | | | | | | | | Evolent | | | Second Quarter 2023 Results | | | | | | August 2, 2023 | | | CONTACT: | | | Seth R. Frank | | | Evolent Investor Relations | | | sfrank@evolent.com | | These statements are only predictions based on our current expectations and projections about future events. Forward-looking statements involve risks and uncertainties that may cause actual results, level of activity, performance or achievements to differ mate ...

Evolent Health, Inc. (NYSE:EVH) Q2 2023 Earnings Conference Call August 2, 2023 5:00 PM ET Company Participants Seth Frank – Vice President-Investor Relations Seth Blackley – Chief Executive Officer John Johnson – Chief Financial Officer Conference Call Participants Jeff Garro – Stephens Sean Dodge – RBC Capital Ryan Daniels – William Blair Charles Rhyee – TD Cowan David Larsen – BTIG Sandy Draper – Guggenheim Jessica Tassan – Piper Sandler Richard Close – Canaccord Genuity Jailendra Singh – Truist Operator ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________ FORM 10-Q _________________________ (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 _________________________ Evolent Health, Inc. (Exact name of registra ...

Evolent Health, Inc. (NYSE:EVH) Q1 2023 Results Conference Call May 3, 2023 5:00 PM ET Company Participants Seth Frank - VP, IR Seth Blackley - CEO John Johnson - CFO Conference Call Participants Sandy Draper - Guggenheim Partners Anne Samuel - JP Morgan Charles Rhyee - TD Cowen David Larsen - BTIG Jailendra Singh - Truist Jeff Garro - Stephens Jessica Tassan - Piper Sandler Richard Close - Canaccord Genuity Ryan Daniels - William Blair Sean Dodge - RBC Capital Markets Operator Welcome to Evolent Health's E ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________ FORM 10-Q _________________________ (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37415 _________________________ Evolent Health, Inc. (Exact name of registr ...